Search - tctmd.com

Displaying 21 - 31 of 31

Sort: Relevancy | Date

Presentation ACC 2022

Updated Cumulative Results Of Treatment With Mavacamten From The EXPLORER-LTE Cohort Of The MAVA-LTE Study In Patients With Obstructive Hypertrophic Cardiomyopathy

Presenter: Florian Rader

April 04, 2022

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Shelley Wood

April 03, 2022

News Conference News ACC 2022

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

Yael L. Maxwell

April 02, 2022

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Shelley Wood

March 28, 2022

News Conference News ACC 2021

‘Enormous’ QoL Improvements With Mavacamten in HCM

Shelley Wood

May 15, 2021

Podcast TCTMD Talking Points

The EXPLORER-HCM Trial

March 17, 2021

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Conference News ESC 2020

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

Michael O'Riordan

August 29, 2020

News Daily News

Mavacamten Successful in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM

Shelley Wood

May 11, 2020

Video

» Interview

Updated Cumulative Results of Treatment with Mavacamten from the EXPLORER-LTE Cohort of the MAVA-LTE Study in Patients with Obstructive Hypertrophic Cardiomyopathy

May 4, 2022

Video

» Interview

ACC 2022: VALOR-HCM - Mavacamten As An Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy

April 3, 2022

Advertisement

Updated Cumulative Results Of Treatment With Mavacamten From The EXPLORER-LTE Cohort Of The MAVA-LTE Study In Patients With Obstructive Hypertrophic Cardiomyopathy

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

What’s Going to Be Hot at ACC 2022, In Person or Virtual

‘Enormous’ QoL Improvements With Mavacamten in HCM

The EXPLORER-HCM Trial

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

Mavacamten Successful in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM

Updated Cumulative Results of Treatment with Mavacamten from the EXPLORER-LTE Cohort of the MAVA-LTE Study in Patients with Obstructive Hypertrophic Cardiomyopathy

ACC 2022: VALOR-HCM - Mavacamten As An Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content